114 related articles for article (PubMed ID: 25129084)
1. [Efficacy and safety of panitumumab for K-ras wild-type unresectable or recurrent colorectal cancer - a study focusing on first-line treatment].
Mitomo S; Suto T; Umemura A; Ishida K; Kanno K; Takeda D; Fujita T; Otsuka K; Nitta H; Uesugi N; Sugai T; Wakabayashi G
Gan To Kagaku Ryoho; 2014 Jun; 41(6):731-5. PubMed ID: 25129084
[TBL] [Abstract][Full Text] [Related]
2. Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.
Pietrantonio F; Cremolini C; Aprile G; Lonardi S; Orlandi A; Mennitto A; Berenato R; Antoniotti C; Casagrande M; Marsico V; Marmorino F; Cardellino GG; Bergamo F; Tomasello G; Formica V; Longarini R; Giommoni E; Caporale M; Di Bartolomeo M; Loupakis F; de Braud F
Oncologist; 2015 Nov; 20(11):1261-5. PubMed ID: 26446234
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
5. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
[TBL] [Abstract][Full Text] [Related]
6. Panitumumab in metastatic colorectal cancer.
Hocking CM; Townsend AR; Price TJ
Expert Rev Anticancer Ther; 2013 Jul; 13(7):781-93. PubMed ID: 23802848
[TBL] [Abstract][Full Text] [Related]
7. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
8. [Two cases of metastatic colorectal cancer in wild-type K-RAS effectively treated by panitumumab].
Ishiyama Y; Kotake M; Matsunaga M; Kitamura H; Yamamoto M; Inaki N; Kurokawa M; Bando H; Yamada T
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1567-70. PubMed ID: 23064074
[TBL] [Abstract][Full Text] [Related]
9. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
[TBL] [Abstract][Full Text] [Related]
10. Panitumumab: in metastatic colorectal cancer with wild-type KRAS.
Weber J; McCormack PL
BioDrugs; 2008; 22(6):403-11. PubMed ID: 18998757
[TBL] [Abstract][Full Text] [Related]
11. Sweeping KRAS generalizations: are we depriving patients of an effective treatment? A novel KRAS mutation and dramatic response to panitumumab in a patient with metastatic colorectal cancer.
Zikria J; Krishnamoorthy S; Kaley K; Saif MW
Int J Colorectal Dis; 2011 Oct; 26(10):1353-4. PubMed ID: 21229361
[No Abstract] [Full Text] [Related]
12. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
[TBL] [Abstract][Full Text] [Related]
13. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.
Freeman DJ; Juan T; Reiner M; Hecht JR; Meropol NJ; Berlin J; Mitchell E; Sarosi I; Radinsky R; Amado RG
Clin Colorectal Cancer; 2008 May; 7(3):184-90. PubMed ID: 18621636
[TBL] [Abstract][Full Text] [Related]
14. Panitumumab - an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status.
Elez E; Alsina M; Tabernero J
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S15-6. PubMed ID: 20189055
[No Abstract] [Full Text] [Related]
15. Panitumumab safety for treating colorectal cancer.
Stremitzer S; Sebio A; Stintzing S; Lenz HJ
Expert Opin Drug Saf; 2014 Jun; 13(6):843-51. PubMed ID: 24766434
[TBL] [Abstract][Full Text] [Related]
16. [A retrospective analysis of cetuximab or panitumumab monotherapy for KRAS wild-type metastatic colorectal cancer in clinical practice].
Sugaya A; Moriwaki T; Tajima D; Imanishi M; Hamano Y; Kobayashi M; Akutsu D; Kobayashi K; Ochi D; Yamada T; Yamamoto Y; Endo S; Suzuki H; Hyodo I
Gan To Kagaku Ryoho; 2015 Feb; 42(2):189-93. PubMed ID: 25743137
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
18. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
[TBL] [Abstract][Full Text] [Related]
19. [Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].
Yoda Y; Yoshino T; Kadowaki S; Bando H; Okano S; Fukushima H; Fuse N; Tahara M; Doi T; Ohtsu A
Gan To Kagaku Ryoho; 2009 Jun; 36(6):1003-6. PubMed ID: 19542725
[TBL] [Abstract][Full Text] [Related]
20. Integration of panitumumab into the treatment of colorectal cancer.
Gravalos C; Cassinello J; García-Alfonso P; Jimeno A
Crit Rev Oncol Hematol; 2010 Apr; 74(1):16-26. PubMed ID: 19616446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
